Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.
Hepatitis B virus (HBV) reactivation is a well-known risk during chemotherapy for hematological malignancies with reported rates ranging between 14% and 72%. However, there is a paucity of data regarding HBV infection management and reactivation risk in patients receiving systemic treatments for solid tumors.



We conducted a PubMed search for publications from January 1990 until May 2016 related to HBV reactivation. The search terms were 'hepatitis B reactivation', cross-referenced with 'chemotherapy', then 'hepatitis B' cross-referenced with International Non-proprietary Name of each of the most used chemotherapy drugs in solid tumors.



From these data, a grading of HBV reactivation risk and recommendations for management are given for most frequently used anticancer drugs in solid tumors.



Most drugs used for the treatment of solid tumors can induce hepatitis B reactivation in HBs antigen-positive patients. HBV screening can be recommended before systemic treatment initiation. Pre-emptive antiviral treatment can reduce the risk of HBV reactivation and prevent chemotherapy disruption.
Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
C S
CS
Voican
Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif olivier.mir@gustaveroussy.fr.
O
O
Mir
CIC Vaccinologie, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
P
P
Loulergue
Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
M
M
Dhooge
Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
C
C
Brezault
Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
J
J
Dréanic
Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
S
S
Chaussade
Hepatology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.|Inserm USM20, Institut Pasteur, Paris, France.
S
S
Pol
Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
R
R
Coriat
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects; D006509:Hepatitis B / Q000139:chemically induced / Q000473:pathology* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D000069283:Rituximab / Q000009:adverse effects; D014775:Virus Activation / Q000187:drug effects
D000970:Antineoplastic Agents; D000069283:Rituximab; D004317:Doxorubicin
chemotherapy; hepatitis B reactivation; immunotherapy; monoclonal antibodies; solid tumors; tyrosine kinase inhibitors